GSK Launches Relvar For Asthma In Japan, First ICS/LABA Administered Once A Day

GlaxoSmithKline has launched Relvar and Ellipta (fluticasone furoate/vilanterol) for bronchial asthma in Japan.

GlaxoSmithKline launched Relvar and Ellipta (fluticasone furoate / vilanterol) for bronchial asthma in Japan, the company announced Dec. 9. The drug is the first ICS/LABA combination drug that is effective for 24 hours and is administered just once a day. The prices for the two products are ¥2,816.80 ($27.37) and ¥3,143.90 respectively, with sales expected to peak at ¥24 billion with 1.3 million patients. GSK launched Advair, a twice-a-day ICS/LABA combination in 2007, and sales of that product were at ¥50.3 billion in 2012. Approximately 8% of the Japanese population suffers from bronchial asthma. (Click Here For More – Japanese Language

)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Japan

China Sentences Astellas Employee To 3.5 Years In Prison On Spy Charges

 
• By 

An employee of Astellas faces three and a half years in prison after sentencing by a court in China on espionage charges.

Activist Investor Vs. Japan Pharma: ASKA Plans Poison Pill As Dalton Pushes For MBO

 
• By 

While ASKA plans to dilute the holding of largest investor Dalton by issuing new shares, the US investment firm continues to push a management buyout option to the mid-sized Japanese pharma company.

Taiho’s Oral, Mutation-Agnostic DMD Candidate Misses Phase III Endpoint

 
• By 

The oral, twice-daily candidate was expected to control decline in motor function in DMD patients regardless of their gene mutations.

Beyond AI Hype: Tokyo-1’s Real Answer On How To Innovate Pharma R&D

 
• By 

Bringing supercomputing power to bear on large-scale calculations for pharma R&D, Tokyo-based Xeureka explains the practical use of AI to empower innovation beyond the hype.

More from Focus On Asia

Sino Biopharm Scoops LaNova In Chinese Pharma’s Biggest Biotech Buyout So Far

 

Sino Biopharm will pay almost $1bn to acquire what target LaNova’s CEO described as an “exploding” pipeline, which includes six clinical-stage candidates in the oncology area.

China Sentences Astellas Employee To 3.5 Years In Prison On Spy Charges

 
• By 

An employee of Astellas faces three and a half years in prison after sentencing by a court in China on espionage charges.

Sun’s Alopecia Treatment Debuts In US - Can It Make Up For Lost Time?

 

Sun’s Leqselvi goes up against Lilly's Olumiant and Pfizer's Litfulo, which currently has the broadest label, in the US alopecia market. Can it shake things up early, amid growing activity in the space with several new mechanisms of action being investigated?